Rates of autism diagnoses are on the rise. While no one knows for sure why, a new study explores whether the increased use of antidepressants during pregnancy might be one of the causes.
In October of 2004, the FDA announced to drug companies that they should add black-box warnings about the risk of suicidal behavior in children and adolescents started on antidepressants. How have these black-box warnings affected clinical practice over the past decade?
This Expert Q&A covers key things that John Walkup, MD, looks for in child and adolescent patients with depression to determine how they are likely to respond to different kinds of medication.
On July 10, the U.S. Food and Drug Administration (FDA) approved Otsuka and Lundbeck’s Rexulti (brexpiprazole) for schizophrenia and as an add-on to antidepressants for adults with depression. As the name suggests, it’s chemically and structurally related to aripiprazole (Abilify).
Learn about Trauma Systems Therapy (TST) and its use with young patients in an interview with Glenn Saxe, MD, Arnold Simon professor and chair, Department of Child and Adolescent Psychiatry, and director, the Child Study Center.
The psychiatric community continues to debate the value of the US Food and Drug Administration's (FDA) so-called ‘black box’ warning on certain antidepressants, and a pair of opposing viewpoints was recently featured in the New England Journal of Medicine.
Brief depression screening questionnaires are popular, especially with primary care providers (PCPs). However, a new study suggests that PCPs who use these questionnaires might be prescribing antidepressants to patients who don’t need them.
Concerns about the possible risk of suicide in young people taking antidepressants are often voiced by experts and parents. But how much of a role does dosage play in the risk of suicide and self-harm among young people on antidepressants?
Concerns about the safety of psychiatric medications during pregnancy are common among psychiatrists and patients alike. In many cases, one must weigh the risks of a medication to mother or child against the risks inherent in untreated mental illness. Recent research, however, lends support to the growing data about the safety of antidepressant medications in pregnancy.
A new drug is showing rapid, long-lasting results in early rodent studies, according to a paper presented by Jeffrey Talbot of Roseman University of Health Sciences at the annual meeting of the Federation of American Societies of Experimental Biology (FASEB) in April.
What steps should clinicians take if psychopharmacologic treatments and school behavioral strategies are insufficient for managing a child with ADHD? We've all been there. ADHD,...